Accueil Ernstrade Bourse Actualite Stock
 
plus500

Place de cotation: Francfort

The Group's principal activity is discovery and development of novel peptide based drugs. The Group focus on the capitalization of the potential of peptidomimetic and small molecule substrates transformed by Group's novel drug discovery method to therapeutic drugs. The Group operates through two business segments Jerini Pharma and Peptide Technologies. The Jerini Pharma segment is engaged in the discovery and development of targeted therapeutics for hereditary angioedema, liver cirrhosis, cancer and inflammatory diseases. The Peptide Technologies segment serves the life science industry and research community by producing custom and catalogue peptides using its integrated array-based technology platforms.

http://www.jerini.com


Copyright  2010  Ernstrade.com